In people who are deficient in CYP2D6, coadministration of modafinil with substrates of CYP2D6 that have ancillary routes of elimination by CYP2C19 (eg, tricyclic antidepressants and selective serotonin reuptake inhibitors) may possibly result in elevated circulating amounts of these medicine and need dose adjustment (Robertson et al 2000; PROVIGIL

Article Under Review